-
Malaria parasite resistance to azithromycin is not readily transmitted by mosquitoes
02 Apr 2024 13:15 GMT
… alone eradicating, malaria1. Resistant parasites emerge, spread geographically and eventually … for selection. Parasite cultures containing 5×108 parasites were treated … parasite lines using an Isolate II Genomic DNA Kit (Bioline, Meridian Bioscience …
-
Parasitology and Mycology Rapid Tests and Point of Care (POC) Pipeline Research Report 2023 - ResearchAndMarkets.com
16 Jan 2024 12:59 GMT
… provides comprehensive information about the Parasitology & Mycology pipeline … report provides extensive coverage of Parasitology & Mycology under development … of Technology
McGill University
Meridian Bioscience Inc
Microbiologics Inc
MiraVista …
-
Meridian Bioscience Reports Second Quarter 2017 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance
27 Apr 2017 11:45 GMT
… 27, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported … fifteen years in detecting these parasites. We have seen rapid clinical … . Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700 …
-
Meridian Bioscience, Inc. Comments on Preliminary Fiscal 2016 Operating Results and Provides Fiscal 2017 Revenue and Earnings Guidance
18 Oct 2016 20:30 GMT
… 18, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today … upper respiratory infections; serology, parasitology and fungal disease diagnosis, and … Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone: 513.271. …
-
Meridian Bioscience Expands Its Portfolio and Launches First Analyte Specific Reagent (ASR) Products
23 Aug 2016 13:00 GMT
… 23, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced … upper respiratory infections; serology, parasitology and fungal disease diagnosis, and … Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271. …
-
Meridian Bioscience Reports Third Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2016 Guidance
28 Jul 2016 12:00 GMT
… 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported … and upper respiratory infections; serology, parasitology and fungal disease diagnosis, and …
-
Meridian Bioscience, Inc. Receives FDA Clearance for New Molecular Test for the Detection of Mycoplasma pneumoniae
15 Jun 2016 12:30 GMT
… 15, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced … and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In …
-
Meridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
28 Apr 2016 11:45 GMT
… 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., (NASDAQ:VIVO) today: reported … and upper respiratory infections; serology, parasitology and fungal disease diagnosis, and …
-
Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae
27 Apr 2016 11:00 GMT
… 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today … implementation of control measures. About Meridian Bioscience, Inc
Meridian is a fully … and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In …
-
Meridian Bioscience Acquires Magellan Diagnostics, Inc.
24 Mar 2016 20:15 GMT
… 24, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ … , “By joining forces with Meridian Bioscience, Magellan Diagnostics will better achieve … upper respiratory infections, serology, parasitology and fungal disease diagnosis. In …
About
© 1995-2025